FDA’s Nonenforcement Actions Are Not Reviewable, Agency Argues In KV’s Makena Suit

The agency says its decisions not to take enforcement action against pharmacies compounding hydroxyprogesterone are discretionary and that KV has not shown that payers are likely to change their reimbursement policies if the court follows its request.